Your browser is no longer supported. Please, upgrade your browser.
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.13 Insider Own0.70% Shs Outstand87.08M Perf Week9.80%
Market Cap6.18B Forward P/E- EPS next Y-4.27 Insider Trans4.87% Shs Float83.19M Perf Month-23.38%
Income-486.10M PEG- EPS next Q-1.13 Inst Own75.50% Short Float5.51% Perf Quarter-12.06%
Sales645.60M P/S9.57 EPS this Y26.80% Inst Trans0.17% Short Ratio4.22 Perf Half Y2.82%
Book/sh5.88 P/B11.85 EPS next Y9.70% ROA-17.40% Target Price123.21 Perf Year-22.05%
Cash/sh18.05 P/C3.86 EPS next 5Y- ROE-86.40% 52W Range61.31 - 101.24 Perf YTD-22.61%
Dividend- P/FCF- EPS past 5Y-6.40% ROI-32.20% 52W High-31.16% Beta1.38
Dividend %- Quick Ratio5.10 Sales past 5Y236.40% Gross Margin86.40% 52W Low13.67% ATR4.42
Employees866 Current Ratio5.90 Sales Q/Q31.60% Oper. Margin-82.00% RSI (14)40.25 Volatility7.32% 6.54%
OptionableYes Debt/Eq2.33 EPS Q/Q75.90% Profit Margin-75.30% Rel Volume0.60 Prev Close66.88
ShortableYes LT Debt/Eq2.33 EarningsNov 03 AMC Payout- Avg Volume1.09M Price69.69
Recom1.90 SMA20-8.13% SMA50-14.07% SMA200-12.13% Volume654,589 Change4.20%
Jan-05-22Reiterated Needham Buy $157 → $150
Dec-09-21Upgrade Oppenheimer Perform → Outperform $125
Nov-05-21Upgrade JP Morgan Neutral → Overweight $130
Sep-15-21Upgrade Guggenheim Neutral → Buy
Aug-05-21Upgrade JP Morgan Underweight → Neutral $92 → $87
Jun-15-21Initiated BTIG Research Buy $110
Apr-26-21Resumed Credit Suisse Neutral $72
Jan-12-21Downgrade Citigroup Buy → Neutral $215 → $108
Jan-11-21Downgrade UBS Buy → Neutral
Jan-08-21Downgrade Raymond James Outperform → Mkt Perform
Jan-08-21Downgrade Morgan Stanley Overweight → Equal-Weight $95
Jan-08-21Downgrade JP Morgan Overweight → Underweight $96
Nov-11-20Initiated Berenberg Hold
Oct-28-20Initiated UBS Buy $212
Aug-25-20Initiated Raymond James Outperform $200
Aug-20-20Downgrade Credit Suisse Outperform → Neutral $185 → $167
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jan-19-22 05:38PM  
Jan-17-22 11:27AM  
Jan-12-22 09:38AM  
Jan-11-22 10:22AM  
Jan-10-22 10:50AM  
Jan-06-22 08:32AM  
Dec-31-21 08:45PM  
10:30AM  
Dec-28-21 09:50AM  
Dec-27-21 10:15AM  
Dec-25-21 11:38AM  
Dec-23-21 11:57AM  
Dec-22-21 11:35AM  
10:27AM  
Dec-21-21 11:24AM  
06:53AM  
Dec-20-21 11:07AM  
Dec-17-21 01:38PM  
10:35AM  
10:06AM  
Dec-16-21 10:00AM  
09:38AM  
Dec-15-21 07:38PM  
11:16AM  
Dec-14-21 03:17PM  
02:41PM  
11:06AM  
Dec-13-21 11:38PM  
10:33AM  
Dec-10-21 10:21AM  
09:58AM  
08:44AM  
Dec-09-21 11:38AM  
09:13AM  
Dec-08-21 07:38PM  
07:38PM  
07:38PM  
Dec-03-21 03:30PM  
12:22PM  
11:31AM  
09:23AM  
Dec-02-21 10:13AM  
09:43AM  
Nov-30-21 06:17PM  
04:20PM  
10:41AM  
09:16AM  
Nov-29-21 10:00AM  
Nov-26-21 02:33PM  
08:46AM  
Nov-25-21 10:56AM  
Nov-23-21 11:08AM  
Nov-22-21 08:18PM  
11:23AM  
Nov-18-21 10:27AM  
Nov-17-21 10:07AM  
08:31AM  
08:30AM  
Nov-12-21 12:56PM  
10:53AM  
Nov-11-21 10:15AM  
Nov-10-21 09:54AM  
Nov-04-21 06:23PM  
10:08AM  
04:31AM  
Nov-03-21 05:25PM  
04:01PM  
Nov-02-21 04:30PM  
Oct-29-21 06:15PM  
Oct-27-21 08:30AM  
Oct-20-21 07:00AM  
Oct-19-21 09:25AM  
Oct-14-21 04:11PM  
Oct-13-21 09:15PM  
04:47PM  
06:26AM  
03:28AM  
Oct-12-21 06:40PM  
04:04PM  
04:04PM  
04:01PM  
10:37AM  
Oct-11-21 03:25PM  
09:13AM  
Oct-08-21 01:02PM  
Oct-07-21 12:14PM  
Oct-06-21 10:11AM  
Oct-05-21 11:33AM  
Oct-04-21 04:30PM  
07:00AM  
Sep-30-21 07:06PM  
Sep-27-21 08:30AM  
Sep-17-21 12:32PM  
Sep-14-21 08:30AM  
Sep-07-21 04:30PM  
08:30AM  
Sep-03-21 11:31AM  
Aug-31-21 05:57PM  
Aug-24-21 11:32AM  
Aug-05-21 09:23AM  
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BEHRENS M KATHLEENDirectorDec 15Option Exercise10.085,00050,400135,517Dec 16 08:00 PM
GRAY MARY ANNDirectorDec 10Option Exercise0.0096709,403Dec 14 08:02 PM
Rodino-Klapac LouiseHead of R&D, CSONov 24Buy79.333,780299,86765,678Nov 29 08:00 AM
INGRAM DOUGLAS SPresident & CEONov 17Buy79.9425,0262,000,578365,082Nov 17 06:24 PM
BEHRENS M KATHLEENDirectorMar 10Option Exercise42.305,000211,500135,517Mar 10 08:04 PM
BEHRENS M KATHLEENDirectorMar 10Sale85.765,000428,800130,517Mar 10 08:04 PM
Wigzell Hans Lennart RudolfDirectorMar 08Option Exercise34.9210,000349,20026,518Mar 10 08:03 PM
Wigzell Hans Lennart RudolfDirectorMar 08Sale83.5110,000835,10016,518Mar 10 08:03 PM